Gingko mihuan

Drug Profile

Gingko mihuan

Alternative Names: Gingko Mihuan - Tianyin Pharmaceuticals; Gingko Mihuan - TPI; GMOL

Latest Information Update: 29 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tianyin Pharmaceutical
  • Class Cardiovascular therapies; Flavonoids; Glycosides; Terpenes; Traditional-Chinese-medicine
  • Mechanism of Action Antioxidants; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angina pectoris; Cardiovascular disorders; Cerebral infarction; Cerebral ischaemia; Coronary disorders; Memory disorders; Neurological disorders; Stroke

Most Recent Events

  • 24 Dec 2014 Tianyin Pharmaceuticals and an undisclosed company entered into a research and development agreement for formulation varieties of gingko mihuan
  • 17 Jul 2012 Launched for Angina pectoris in China (PO) before July 2012
  • 17 Jul 2012 Launched for Cardiovascular disorders in China (PO) before July 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top